Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antipsychotic Discontinuation in Alzheimer's Disease

Trial Profile

Antipsychotic Discontinuation in Alzheimer's Disease

Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Risperidone (Primary)
  • Indications Aggression; Agitation; Alzheimer's disease; Psychotic disorders
  • Focus Therapeutic Use
  • Acronyms ADAD
  • Most Recent Events

    • 18 Oct 2012 Primary endpoint 'Time-to-relapse' has been met.
    • 18 Oct 2012 Results published in the New England Journal of Medicine.
    • 19 Jul 2012 Results presented at the 2012 International Conference on Alzheimer's Disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top